TY  - CHAP
M1  - Book, Section
TI  - Pneumocystis Pneumonia
A1  - Martin, Stanley I.
A1  - Fishman, Jay A.
A2  - Grippi, Michael A.
A2  - Elias, Jack A.
A2  - Fishman, Jay A.
A2  - Kotloff, Robert M.
A2  - Pack, Allan I.
A2  - Senior, Robert M.
A2  - Siegel, Mark D.
PY  - 2015
T2  - Fishman's Pulmonary Diseases and Disorders, 5e
AB  - Despite  widespread  use  of  effective  antimicrobial  prophylaxis  in  susceptible  immunocompromised  patient  populations,  Pneumocystis  jiroveci  remains  an  important  opportunistic  pathogen.  The  incidence  of  Pneumocystis  pneumonia  (PCP)  has  decreased  with  the  appropriate  deployment  of  antimicrobial  prophylaxis  in  susceptible  hosts  and  with  the  advent  of  highly  effective  antiretroviral  therapy  (HAART)  in  HIV-infected  individuals.  PCP  remains,  however,  an  important  syndrome  in  HIV  infection  in  the  developing  world  with  high  mortality.  Pneumocystis  also  impacts  the  growing  population  of  immunocompromised  individuals  following  organ  and  hematopoietic  stem  cell  and  bone  marrow  transplantation,  and  with  the  broader  use  of  immunosuppressive  therapies  in  connective  tissue,  cancer,  and  immune  disorders.  The  change  in  nomenclature  this  past  decade,  renaming  of  Pneumocystis  carinii  as  P.  jiroveci,  reflects  knowledge  about  the  organisms  responsible  for  this  syndrome  in  different  host  species.  This  change  has  generated  significant  controversy  among  scientists,  clinicians,  and  journal  editors.  Advocates  and  detractors  alike  agree  that  no  matter  the  species  name,  Pneumocystis  pneumonia  or  PCP  should  continue  to  be  used  to  describe  disease  caused  by  this  organism  in  humans.  
SN  - 
PB  - McGraw-Hill Education
CY  - New York, NY
Y2  - 2023/03/31
UR  - accessmedicine.mhmedical.com/content.aspx?aid=1122370457
ER  -